Patrick Rericha PhD

Cross-functional & Translational Work: • Leading development and scale-up of stem cell-derived processes with consideration of quality, reproducibility, and regulatory requirements for advanced therapies (ATMPs). • Supporting alignment of process development activities with CMC and clinical development needs. • Contributing to documentation frameworks, including SOPs, risk assessments, and structured data reporting to support development decisions. • Driving technology transfer between international sites, ensuring consistency and compliance across processes. • Collaborating across scientific, operational, and strategic functions to align development with downstream regulatory expectations. Leadership & Oversight: • Oversight of lab operations, including supervision and hiring, within a quality-focused and structured environment. • Contributing to business strategy, stakeholder communication, and fundraising. Supporting the translation of scientific research into clinically and commercially viable assets.

Lab & Technical Experience: • Development, scale-up and QC of stem cell-derived cardiovascular cell differentiation processes from lab to commercial scale. • Assay development (drug screening, toxicology). • Technology transfer between international sites, authoring of SOPs, and writing of risk assessments. • Oversight of lab operations including supervisions and candidate interviews. Business & Startup Involvement: • Contribution to business plan, pitch deck, fundraising efforts, and stakeholder outreach. • Management of inventory systems and support of brand development (web, flyers, merchandise).

• Designed and scaled bioprocess systems for stem cell applications, contributing to robust and reproducible process development. • Supported development of scalable platforms with relevance for manufacturing and regulatory expectations. • Worked on process optimization and downstream workflows in alignment with quality and translational requirements.

Studying epicardium to improve stem cell therapy for cardiac repair: • Determining the effects of hESC-epicardial paracrine signalling factors on cardiovascular cells using hESC- and hiPSC-derived cardiomyocytes as a model. • Isolation and characterisation of extracellular vesicles / exosomes from cell supernatant and identification of their cargo using miRNA-sequencing and proteomics approaches. • Screening of identified miRNA and protein candidates in vitro and in vivo, including tube formation, engineered heart tissue, and chick vascularisation assays. • Generated complex datasets supporting translational insights relevant for future clinical and regulatory development of stem cell therapies.

Three rotations at the stem cell institute as part of the Wellcome MRes plus PhD programme in stem cell biology and medicine: • Chalut lab: Studying mechanosensing and the effects of stiffness on ESC differentiation using "StemBond" hydrogel technology. • Basu lab: Investigating FGF4 delivery in mouse ESCs using single molecule tracking. • Sinha lab: Studying the effects of hESC-epicardial extracellular vesicles on hESC-cardiomyocyte maturation. The basis for my PhD project.

Cell type development: • Forward programming of human iPSCs using inducible gene targeting strategies. • Optimisation of culture conditions including media screens and storage. • Scale-up of established cell types for manufacturing including animal cells for lab grown meat.

Promoter studies in upstream process development: • Introduction of different promoter types in E. coli to improve POI production yields. • Assisted in the setup of DoE and carried out the respective experiments using a fully automated high-throughput cultivation prototype. • Working in compliance with GLP/GMP.

Investigating post translational modifications in CNS remyelination: • Knock-out studies in primary rat/mouse oligodendrocytes using CRISPR/Cas9 gene editing. • Setup of an organotypic rat/mouse brain slice culture for drug screening. • Lentivirus production.